Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo
- PMID: 15388991
- DOI: 10.1159/000079991
Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo
Abstract
Superinfection by HIV-1 of a cell line containing the complete murine leukemia virus (MuLV) genome was shown to give rise to pseudotyped HIV-1/MuLV. Such superinfection was successful with certain strains of HIV-1 subtypes A-D. Primary spleen cells and cells of the peritoneal cavity of immunocompetent mice of the C57Bl/6 strain were infectable with the pseudotype HIV-1/MuLV and secreted HIV-1 in vitro and in vivo. In contrast, the murine cell lines, NIH 3T3, myeloma cell line Sp2/0, and two murine hybridoma cell lines were relatively resistant to infection and produced no or little HIV. After primary murine spleen cells had been infected with pseudotyped HIV-1 and transferred to C57Bl/6 mice, replication-competent HIV-1 was obtained from the peritoneal cavity for at least 10-14 days. High amounts (> 10(5) vRNA copies/ml) of HIV-1 vRNA could be measured in the peritoneal fluid. Presence of HIV-1 proviral DNA was detectable in cells from the peritoneal cavity for up to 24 days after infected cell transfer. Active reverse transcriptase representing both HIV-1 and C-type murine retroviruses was detected in the peritoneal washes. The HIV-infected spleen cells injected into the peritoneal cavity elicited HIV-1-specific cellular immune responses to p24gag, gp160Env, Nef, Tat and Rev. Mice immunized with HIV-1 DNA, but not with HIV-1 protein, cleared their HIV-1-infected cells within 10-14 days after challenge with HIV-1/MuLV-infected syngeneic spleen cells. This novel model system of primarily cellular reactivity to HIV-1-infected cells in vivo may become useful for assaying experimental HIV-1 immunization schedules.
Copyright 2004 S. Karger AG, Basel
Similar articles
-
Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.Vaccine. 2007 Mar 1;25(11):2145-54. doi: 10.1016/j.vaccine.2006.10.057. Epub 2006 Nov 13. Vaccine. 2007. PMID: 17254672
-
Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.Vaccine. 2009 Oct 30;27(46):6424-31. doi: 10.1016/j.vaccine.2009.06.016. Epub 2009 Jun 21. Vaccine. 2009. PMID: 19549607
-
Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.Vaccine. 2007 Sep 28;25(39-40):6882-90. doi: 10.1016/j.vaccine.2007.07.012. Epub 2007 Jul 27. Vaccine. 2007. PMID: 17707956
-
Retroviral superinfection resistance.Retrovirology. 2005 Aug 18;2:52. doi: 10.1186/1742-4690-2-52. Retrovirology. 2005. PMID: 16107223 Free PMC article. Review.
-
The pathogenic role of human immunodeficiency virus accessory genes in transgenic mice.Curr Top Microbiol Immunol. 1995;193:133-56. doi: 10.1007/978-3-642-78929-8_8. Curr Top Microbiol Immunol. 1995. PMID: 7648873 Review. No abstract available.
Cited by
-
Advancing the preclinical study of comorbid neuroHIV and substance use disorders: Current perspectives and future directions.Brain Behav Immun. 2023 Oct;113:453-475. doi: 10.1016/j.bbi.2023.07.021. Epub 2023 Aug 9. Brain Behav Immun. 2023. PMID: 37567486 Review.
-
Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.Sci Rep. 2018 May 24;8(1):8078. doi: 10.1038/s41598-018-26281-z. Sci Rep. 2018. PMID: 29799015 Free PMC article.
-
DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant.Vaccines (Basel). 2013 Sep 25;1(4):415-43. doi: 10.3390/vaccines1040415. Vaccines (Basel). 2013. PMID: 26344341 Free PMC article.
-
Rodent models for HIV-associated neurocognitive disorders.Trends Neurosci. 2012 Mar;35(3):197-208. doi: 10.1016/j.tins.2011.12.006. Epub 2012 Feb 1. Trends Neurosci. 2012. PMID: 22305769 Free PMC article. Review.
-
A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness.Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3760-5. doi: 10.1073/pnas.0500649102. Epub 2005 Feb 23. Proc Natl Acad Sci U S A. 2005. PMID: 15728729 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical